1197-66-6

Basic information

• Product Name: 2,2,6,6-tetramethyl-2H-3,5,6-trihydropyran-4-one
• Synonyms: 2,2,6,6-tetramethyl-2H-3,5,6-trihydropyran-4-one;2,2,6,6-Tetramethyltetrahydro-4H-pyran-4-one;tetrahydro-2,2,6,6-tetraMethylpyran-4-one;2,2,6,6-tetraMethyl-tetrahydropyran-4-one;4H-Pyran-4-one,tetrahydro-2,2,6,6-tetraMethyl-;Tetrahydro-2,2,6,6-tetraMethyl-4H-pyran-4-one;2,2,6,6-tetramethyloxan-4-one;2,2,6,6-tetramethyldihydro-2H-pyran-4(3H)-one
• CAS NO: 1197-66-6
• Molecular Formula: C₉H₁₆O₂
• Molecular Weight: 156.23
• Mol File: 1197-66-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 12.8 °C
• Boiling Point: 198.11 °C at 760 mmHg
• Flash Point: 63.687 °C
• Appearance: /
• Density: 0.915 g/cm³
• Vapor Pressure: 0.366mmHg at 25°C
• Refractive Index: 1.422
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2,2,6,6-tetramethyl-2H-3,5,6-trihydropyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,6,6-tetramethyl-2H-3,5,6-trihydropyran-4-one(1197-66-6)
• EPA Substance Registry System: 2,2,6,6-tetramethyl-2H-3,5,6-trihydropyran-4-one(1197-66-6)

Safety Data

• Hazardous Substances Data: 1197-66-6(Hazardous Substances Data)

Usage

Uses

2,2,6,6-Tetramethyl-2h-3,5,6-trihydropyran-4-one is a chemical reagent used in the synthesis of Nodulisporic Acid, a potent and systemic insecticide.

InChI:InChI=1/C9H16O2/c1-8(2)5-7(10)6-9(3,4)11-8/h5-6H2,1-4H3

Upstream product

• 186581-53-3 diazomethane 
• 67-56-1 methanol 
• 60-29-7 diethyl ether 
• 5455-94-7 2,2,5,5-tetramethyltetrahydro-3-oxofuran 
• 389091-69-4 ((S)-2-Methoxymethyl-pyrrolidin-1-yl)-(2,2,6,6-tetramethyl-tetrahydro-pyran-4-ylidene)-amine 
• 3682-91-5 2,6-dihydroxy-2,6-dimethyl-heptan-4-one 
• 504-20-1 phorone 

Downstream Products

• 250649-77-5 4-(2-[1,3]dioxolan-2-yl-phenyl)-2,2,6,6-tetramethyl-tetrahydro-pyran-4-ol 
• 250649-15-1 4-(2-[1,3]dioxolan-2-yl-phenyl)-2,2,6,6-tetramethyl-3,6-dihydro-2H-pyran 
• 250649-23-1 2-(2,2,6,6-tetramethyl-3,6-dihydro-2H-pyran-4-yl)-benzaldehyde 
• 36638-47-8 2,2,6,6-tetramethyl-tetrahydro-pyran-4-one-(2,4-dinitro-phenylhydrazone) 
• 1142363-56-1 2,2,6,6-tetramethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyran 
• 1314398-25-8 (2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)methanol 

Relevant articles and documents

-

-

Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent

Cystic fibrosis (CF) is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR). With the discovery of Ivacaftor and Orkambi, it has been shown that CFTR function can be partially restored by administering one or more small molecules. These molecules aim at either enhancing the amount of CFTR on the cell surface (correctors) or at improving the gating function of the CFTR channel (potentiators). Here we describe the discovery of a novel potentiator GLPG1837, which shows enhanced efficacy on CFTR mutants harboring class III mutations compared to Ivacaftor, the first marketed potentiator. The optimization of potency, efficacy, and pharmacokinetic profile will be described.

SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, and G are defined herein.

THIENO[2,3-C]PYRANS AS CFTR MODULATORS

The present invention discloses compounds according to Formula I: Wherein R is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.